Clinical trials are conducted to collect data regarding the safety and efficacy of new drug and device development. Treatments studied in clinical trials might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. Office visits, lab test, medication, study related procedures, and compensation for time and travel are provided to eligible participants.
CURRENT CLINICAL STUDIES
Insmed Protocol: INS1007-221
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Brensocatib in Participants with Chronic Rhinosinusitis Without Nasal Polyps- The BiRCh Study.
Eli Lilly Protocol: J2T-MC-KGBU
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lebrikizumab/LY3650150 in Adult Participants with Chronic Rhinosinusitis with
Nasal Polypson Background Intranasal Corticosteroids
GSK/Bellus Protocol: BUS-P3-02
A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study with Open-label Extension of BLU-5937in Adult Participants with Refractory Chronic Cough Including UnexplainedChronic Cough (CALM-2)
Sanofi Protocol: ACT18207
A randomized Phase 2, double-blind, placebo-controlled, parallel-group, 2-arm study to assess the
efficacy, safety, and tolerability of subcutaneous lunsekimig ni adult participants with chronic rhinosinusitis with nasal polyps (CRSWNP)
GSK Realiti-N Protocol: 218995
A Multinational, Observational Study to Evaluate the Real-World Effectiveness of Mepolizumab in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSWNP)
lonos Protocol: CPT-2023-06-23
Upstream Bio Protocol: UPB-CP-03
A Phase ,2 Randomized, Double-blind, Placebo-controlled, Multi-center Study ot Assess the Efficacy and
Safety of Verekitug (UPB-101) ni Participants with Chronic Rhinosinusitis with Nasal Polyps on a Background of Nasal Corticosteroids (VIBRANT)
Insmed Protocol: INS1007-221
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of the Efficacy and Safety of Brensocatib in Participants with Chronic Rhinosinusitis Without Nasal Polyps- The BiRCh Study.
Eli Lilly Protocol: J2T-MC-KGBU
A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Lebrikizumab/LY3650150 in Adult Participants with Chronic Rhinosinusitis with
Nasal Polypson Background Intranasal Corticosteroids
GSK/Bellus Protocol: BUS-P3-02
A Phase 3, 24-Week, Randomized, Double-Blind, Placebo-Controlled, Parallel-Arm Efficacy and Safety Study with Open-label Extension of BLU-5937in Adult Participants with Refractory Chronic Cough Including UnexplainedChronic Cough (CALM-2)
Sanofi Protocol: ACT18207
A randomized Phase 2, double-blind, placebo-controlled, parallel-group, 2-arm study to assess the
efficacy, safety, and tolerability of subcutaneous lunsekimig ni adult participants with chronic rhinosinusitis with nasal polyps (CRSWNP)
GSK Realiti-N Protocol: 218995
A Multinational, Observational Study to Evaluate the Real-World Effectiveness of Mepolizumab in Patients with Chronic Rhinosinusitis with Nasal Polyps (CRSWNP)
lonos Protocol: CPT-2023-06-23
Upstream Bio Protocol: UPB-CP-03
A Phase ,2 Randomized, Double-blind, Placebo-controlled, Multi-center Study ot Assess the Efficacy and
Safety of Verekitug (UPB-101) ni Participants with Chronic Rhinosinusitis with Nasal Polyps on a Background of Nasal Corticosteroids (VIBRANT)
Our team can answer questions, discuss your needs and help locate research studies that match your interests.
We can also provide interpreter services for non-English speaking patients. Call 210-545-0404 ext. 1324
CLINICAL RESEARCH TEAM
Primary Investigator: Dr. Jeffrey Rosenbloom
Sub Investigator: Dr. Benjamin Webb
Sub Investigator: Dr. Andamo Guillaume
Senior Research Coordinator: Robert Gonzalez, LVN
Phone: 210-545-0404 ext. 1324
Clinical Research Coordinator: Micheal Shears, MA
Phone: 210-545-0404 ext. 1328